ChronoScale Corporation Common Stock (CHRN) Expected to Post Quarterly Earnings on Monday

ChronoScale Corporation Common Stock (NASDAQ:CHRN) is expected to post its Q2 2026 resultson Monday, July 27th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $2.5130 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($3.89) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.The firm had revenue of $18.09 million during the quarter. On average, analysts expect ChronoScale Corporation Common Stock to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

ChronoScale Corporation Common Stock Trading Down 4.7%

NASDAQ CHRN opened at $21.50 on Friday. The stock has a 50-day moving average of $20.23 and a 200-day moving average of $13.90. The firm has a market cap of $76.54 million, a PE ratio of -4.00 and a beta of 0.99. The company has a current ratio of 1.55, a quick ratio of 1.03 and a debt-to-equity ratio of 0.25. ChronoScale Corporation Common Stock has a 1-year low of $2.91 and a 1-year high of $30.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in ChronoScale Corporation Common Stock by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares during the period. Virtu Financial LLC acquired a new stake in shares of ChronoScale Corporation Common Stock in the third quarter valued at $57,000. Shay Capital LLC acquired a new stake in shares of ChronoScale Corporation Common Stock in the third quarter valued at $67,000. Finally, Citadel Advisors LLC purchased a new position in ChronoScale Corporation Common Stock in the third quarter valued at $198,000. 6.42% of the stock is owned by institutional investors.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.